BD Diagnostics has received CE mark approval for its first healthcare-associated infection (HAI) assay - BD MAX MRSA assay.

BD MAX MRSA Assay is designed to be used on BD MAX automated molecular system to rapidly identify methicillin-resistant Staphylococcus aureus (MRSA) in patients.

The dual functionality of open system and CE/IVD capabilities on the BD MAX System provides clinicians with the best information, which enables them to make critical treatment and management decisions to improve patient care.

BD Diagnostics vice president and general manager Hilja Ibert said the BD MAX MRSA Assay on the BD MAX System provides significant laboratory efficiency and versatility to help address the increasing volume of molecular tests.